Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,220
  • Shares Outstanding, K 12,886
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta 0.94
  • Price/Sales 125.44
  • Price/Cash Flow N/A
  • Price/Book 4.51
Trade LEXX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +270,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +27.03%
on 04/16/24
3.92 -40.05%
on 03/28/24
-1.44 (-37.99%)
since 03/26/24
3-Month
1.42 +65.49%
on 01/29/24
6.85 -65.69%
on 03/11/24
+0.93 (+65.49%)
since 01/26/24
52-Week
0.65 +262.21%
on 06/15/23
6.85 -65.69%
on 03/11/24
+0.09 (+3.98%)
since 04/26/23

Most Recent Stories

More News
Lexaria Bioscience (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board. The potential...

LEXX : 2.35 (+7.31%)
Lexaria (NASDAQ: LEXX) Grows Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally...

LEXX : 2.35 (+7.31%)
Lexaria Bioscience (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will...

LEXX : 2.35 (+7.31%)
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 0.7996 (+12.62%)
LEXX : 2.35 (+7.31%)
Lexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Study

At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar...

LEXX : 2.35 (+7.31%)
Lexaria (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on...

LEXX : 2.35 (+7.31%)
LEXXW : 0.7996 (+12.62%)
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency...

LEXX : 2.35 (+7.31%)
Lexaria to Present at The LD Micro Invitational XIV

Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces...

LEXX : 2.35 (+7.31%)
Lexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with...

LEXX : 2.35 (+7.31%)
Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan,...

LEXX : 2.35 (+7.31%)
LEXXW : 0.7996 (+12.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 2.76
2nd Resistance Point 2.60
1st Resistance Point 2.48
Last Price 2.35
1st Support Level 2.20
2nd Support Level 2.04
3rd Support Level 1.92

See More

52-Week High 6.85
Fibonacci 61.8% 4.48
Fibonacci 50% 3.75
Fibonacci 38.2% 3.02
Last Price 2.35
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar